索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]温贵显,张飞飞,刘惠良.卵圆孔未闭与隐源性卒中[J].国际心血管病杂志,2024,06:367-370.
点击复制

卵圆孔未闭与隐源性卒中(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2024年06期
页码:
367-370
栏目:
综述
出版日期:
2024-12-10

文章信息/Info

Title:
-
作者:
温贵显; 张飞飞; 刘惠良
050017 石家庄，河北医科大学研究生院河北省人民医院心内一科（温贵显）；050057 石家庄，河北省人民医院心血管内一科（张飞飞、刘惠良）
Author(s):
-
关键词:
卵圆孔未闭; 隐源性卒中; 反常性栓塞; 原位血栓
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2024.06.011
文献标识码:
-
摘要:
卵圆孔未闭（PFO）是常见的先天性心脏病，与隐源性卒中紧密相关。PFO相关的反常性栓塞、原位血栓、心房重构导致的血流动力学变化、房间隔膨出瘤等均可致隐源性卒中。PFO合并隐源性卒中的治疗主要包括药物治疗和手术封堵。该文介绍PFO导致隐源性卒中的相关机制及目前指南推荐的治疗方案，旨在为患者提供更好的诊断和治疗。
Abstract:
-

参考文献/References

[1] Calvert PA, Rana BS, Kydd AC, et al. Patent foramen ovale:anatomy, outcomes, and closure[J]. Nat Rev Cardiol, 2011, 8(3):148-160.
[2] Shi F, Sha L, Li H, et al. Recent progress in patent foramen ovale and related neurological diseases: a narrative review[J]. Front Neurol, 2023, 14: 1129062.
[3] Yaghi S, Bernstein RA, Passman R, et al. Cryptogenic stroke:research and practice[J]. Circ Res, 2017, 120(3): 527-540.
[4] Lechat P, Mas JL, Lascault G, et al. Prevalence of patent foramen ovale in patients with stroke[J]. N Engl J Med, 1988, 318(18):1148-1152.
[5] Nakayama R, Takaya Y, Akagi T, et al. Identification of high-risk patent foramen ovale associated with cryptogenic stroke:development of a scoring system[J]. J Am Soc Echocardiogr, 2019, 32(7): 811-816.
[6] Meister SG, Grossman W, Dexter L, et al. Paradoxical embolism[J]. Am J Med, 1972, 53(3): 292-298.
[7] Liu Y, Wu Y, Xiong L. Surgical vs. drug therapy in patients with patent foramen ovale and cryptogenic stroke[J]. Herz, 2021, 46(3): 250-254.
[8] Elsheikh S, Lip GYH, Abdul-Rahim AH. Potential embolic sources in embolic stroke of undetermined source in patients with patent foramen ovale: look harder[J]. Cerebrovasc Dis, 2023, 52(6): 607-608.
[9] Isath A, Malik A, Koziol KJ, et al. Meta-analysis of patent foramen ovale closure for cryptogenic stroke in older versus younger patients[J]. J Am Coll Cardiol, 2023, 81(8): 816.
[10] Yan C, Li H. Preliminary investigation of in situ Thrombus within patent foramen ovale in patients with and without stroke[J]. JAMA, 2021, 325(20): 2116-2118.
[11] Yan C, Li H, Wang C, et al. Frequency and size of in situ Thrombus within patent foramen ovale[J]. Stroke, 2023, 54(5):1205-1213.
[12] Lee MJ, Park SJ, Yoon CH, et al. Association of left atrial enlargement with cortical infarction in subjects with patent foramen ovale[J]. J Stroke, 2016, 18(3): 304-311.
[13] Rigatelli G, Zuin M, Roncon L. Increased blood residence time as markers of high-risk patent foramen ovale[J]. Transl Stroke Res, 2023, 14(3): 304-310.
[14] Rigatelli G, Zuin M, Bilato C. Atrial septal aneurysm contribution to the risk of cryptogenic stroke in patients with patent foramen ovale: a brief updated systematic review and meta-analysis[J]. Trends Cardiovasc Med, 2023, 33(6): 329-333.
[15] Xu L, Zhou C, Pan X, et al. Effect of ASA on the risk of cerebrovascular ischemic events in patients with PFO[J]. Ann Clin Transl Neurol, 2022, 9(9): 1384-1391.
[16] Korniluk A, Koper-Lenkiewicz OM, Kamińska J, et al. Mean platelet volume (MPV): new perspectives for an old marker in the course and prognosis of inflammatory conditions[J]. Mediators Inflamm, 2019, 2019: 9213074.
[17] 周秋曦, 伍伟锋, 孔清, 等. 卵圆孔未闭患者平均血小板体积水平研究[J]. 临床心血管病杂志, 2015, 31(1): 57-60.
[18] Zuin M, Rigatelli G, Rigatelli A, et al. Correlations between serum homocysteine levels and RoPE score in patients with patent foramen ovale[J]. Heart Vessels, 2020, 35(5): 705-711.
[19] Deng W, McMullin D, Inglessis-Azuaje I, et al. Effect of patent foramen ovale closure after stroke on circulatory biomarkers[J]. Neurology, 2021, 97(2): e203-e214.
[20] Shah SR. Interventional closure vs. medical therapy of patent foramen ovale for secondary prevention of stroke: updated meta-analysis[J]. Clin Res Cardiol, 2019, 108(4): 452.
[21] Kasner SE, Rhodes JF, Andersen G, et al. Five-year outcomes of PFO closure or antiplatelet therapy for cryptogenic stroke[J]. N Engl J Med, 2021, 384(10): 970-971.
[22] Wein T, Lindsay MP, C?té R, et al. Canadian stroke best practice recommendations: secondary prevention of stroke, sixth edition practice guidelines, update 2017[J]. Int J Stroke, 2018, 13(4):420-443.
[23] Kuijpers T, Spencer FA, Siemieniuk RAC, et al. Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline[J]. BMJ, 2018, 362: k2515.
[24] Diener HC, die Deutsche Gesellschaft für Neurologie (DGN), GYGU AJ, et al. Kryptogener Schlaganfall und offenes Foramen ovale: S2e-Leitlinie[J]. Nervenarzt, 2018, 89(10): 1143-1153.
[25] Pristipino C, Sievert H, D’Ascenzo F, et al. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism[J]. Eur Heart J, 2019, 40(38): 3182-3195.
[26] Tarantini G, D’Amico G, Baracchini C, et al. Position paper of the Italian society of interventional cardiology (SICI-GISE):management of patent foramen ovale in patients with cerebral or systemic thromboembolism - 2020[J]. G Ital Cardiol (Rome), 2020, 21(4 Suppl 2): 50S-59S.
[27] Mas JL, Derex L, Guérin P, et al. Transcatheter closure of patent foramen ovale to prevent stroke recurrence in patients with otherwise unexplained ischaemic stroke: expert consensus of the French neurovascular society and the French society of cardiology[J]. Arch Cardiovasc Dis, 2019, 112(8/9): 532-542.
[28] Araszkiewicz A, Bartu? S, Demkow M, et al. Interventional closure of patent foramen ovale in prevention of thromboembolic events. Consensus document of the Association of Cardiovascular Interventions and the Section of Grown-up Congenital Heart Disease of the Polish Cardiac Society[J]. Kardiol Pol, 2019, 77(11): 1094-1105.
[29] Messé SR, Gronseth GS, Kent DM, et al. Practice advisory update summary: patent foramen ovale and secondary stroke prevention: report of the guideline subcommittee of the American academy of neurology[J]. Neurology, 2020, 94(20): 876-885.
[30] 张玉顺, 蒋世良, 朱鲜阳. 卵圆孔未闭相关卒中预防中国专家指南[J]. 心脏杂志, 2021, 33(1): 1-10.
[31] Kavinsky CJ, Szerlip M, Goldsweig AM, et al. SCAI guidelines for the management of patent foramen ovale[J]. J Soc Cardiovasc Angiogr Interv, 2022, 1(4): 100039.
[32] Caso V, Turc G, Abdul-Rahim AH, et al. European Stroke Organisation (ESO) Guidelines on the diagnosis and management of patent foramen ovale (PFO) after stroke[J]. Eur Stroke J, 2024:23969873241247978.

备注/Memo

备注/Memo:
基金项目：2024年政府资助临床医学优秀人才培养项目（ZF202401）；2023年度河北省医学科学研究课题计划（20230018）
通信作者：刘惠良，E-mail：15030112599@163.com
更新日期/Last Update: 2024-12-10